Objective:
ST-segment elevation myocardial infarction (STEMI) patients with the multivessel disease have distinctive plaque characteristics in non-IRA lesions. Intensive statin therapy was a potential approach to treat STEMI patients
with the non-IRA disease. However, there is still poor evidence about the therapeutic effect. In this study, we have evaluated
the detailed therapeutic effect of statin plus ezetimibe intensive therapy.
Method:
For STEMI patients with non-IRA disease undergoing primary percutaneous coronary intervention (PCI), 183 control STEMI patients without non-IRA disease undergoing primary PCI, and 200 STEMI patients with non-IRA disease undergoing primary PCI were introduced into this study. 200 STEMI patients with non-IRA disease undergoing primary PCI
were divided into Normal group, Intensive group, Normal & Combined group, and Intensive & Combined group. The baseline information for each participant was recorded. Meanwhile, the physiological and biochemical indicators of each member with different treatments were collected after one-year follow-up.
Result:
For STEMI patients with non-IRA disease undergoing primary PCI, no differences could be detected in multiple indexes such as OCT examination results, age, stroke, etc. However, diabetes mellitus, smoking, and coronary Gensini score
were different between different groups (P<0.05). After one year follow-up, cholesterol, low-density lipoprotein, coronary
Gensini score, thin-cap fibroatheroma, length of non-infarcted arterial lesions, non-infarct artery lesion range, myocardial
infarction again, and revascularization again were significantly different between different groups (P<0.05).
Conclusion:
The results mentioned above suggested that pitavastatin combined with ezetimibe was an effective approach to
STEMI patients with non-IRA disease undergoing primary PCI. The results obtained in this study have provided a novel
way for the treatment of STEMI patients with non-IRA disease undergoing primary PCI.
Minimized contrast use with intravascular ultrasound-guidance percutaneous coronary intervention. One-year follow-up of the MOZART randomized study
